CLLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellectis SA (CLLS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising analyst coverage and potential in the CAR-T therapy space, the technical indicators suggest a bearish trend, and there are no strong trading signals or recent positive news to support immediate investment. The lack of financial performance data and the absence of significant insider or hedge fund activity further reduce the conviction for a buy decision.
The MACD is negatively expanding, RSI is neutral at 36.081, and moving averages are converging, indicating no clear upward momentum. The stock is trading below the pivot level of 3.916, with key support at 3.645. Overall, the technical indicators suggest a bearish trend.
Analyst Bill Maughan initiated coverage with a Buy rating and a $9 price target, citing strong efficacy data from initial programs in hematological cancers.
No recent news or event-driven catalysts. Technical indicators suggest a bearish trend. Stock trend analysis predicts a decline of -4.27% in the next week and -4.1% in the next month. No recent insider or hedge fund activity.
No financial performance data available for analysis. Earnings are expected on 2026-03-12 after hours.
Analyst Bill Maughan from Clear Street initiated a Buy rating with a $9 price target, highlighting strong efficacy data and potential in the CAR-T therapy space.
